natgillin/translations-raw huggingface dataset:
It is not recommended to inject into an IV line delivering glucose 50 mg/ml (5%) in RingerLactate solution for injection, or other IV fluids not listed in this section, as this may cause precipitation from solution.
Ne preporučuje se injicirati ga u i.v. liniju kojom se daje glukoza od 50 mg/ml (5%) u otopini Ringerovog laktata za injekciju ili druge i.v. tekućine koje nisu navedene u ovom dijelu, jer to može prouzročiti precipitaciju iz otopine.
IV line solution compatibility
Kompatibilnost s otopinama za i.v. liniju
Caution should be exercised with respect to monitoring the incision for signs of infection in surgical patients receiving Dynastat.
U kirurških bolesnika koji primaju Dynastat mora se oprezno nadzirati kirurški rez zbog znakova infekcije.
Abnormal sternal serous wound drainage, wound infection Blood and lymphatic system disorders Anaemia postoperative
Poremećaji krvi i limfnog sustava postoperativna anemija trombocitopenija
• glucose 50 mg/ml (5%) solution for infusion
• otopina glukoze 50 mg/ml (5%) za infuziju
OUTER CARTON TEXT: 40 mg powder and solvent for solution for injection
TEKST VANJSKOG PAKIRANJA: 40 mg prašak i otapalo za otopinu za injekciju
OUTER CARTON: 40 mg vials
VANJSKO PAKIRANJE: 40 mg bočice
Thus, each 2 ml of reconstituted solution contains 40 mg of parecoxib.
Tako svakih 2 ml pripremljene otopine sadrži 40 mg parekoksiba.
Gastroduodenal ulceration, gastrooesophageal reflux disease, dry mouth, gastrointestinal sounds abnormal
Poremećaji probavnog sustava mučnina bolovi u abdomenu, povraćanje, konstipacija, dispepsija, flatulencija gastroduodenalni ulkus, gastroezofagealna refluksna bolest, suha usta, neuobičajeni gastrointestinalni zvukovi pankreatitis, ezofagitis, edem usta (perioralno oticanje)
Acute renal failure has been reported through post-marketing surveillance in patients receiving parecoxib (see section 4.8).
Tijekom praćenja bolesnika koji su primali parekoksib nakon njegova stavljanja u promet zabilježeno je akutno zatajenje bubrega (vidjeti dio 4.8).
OUTER CARTON: 40 mg powder and solvent for solution for injection
VANJSKO PAKIRANJE: 40 mg prašak i otapalo za otopinu za injekciju
Dynastat should be inspected visually for particulate matter and discoloration prior to administration.
Prije primjene Dynastata potrebno je provjeriti moguću prisutnost čestica i promjenu boje.
• glucose 50 mg/ml (5%) solution for infusion;
• otopina glukoze 50 mg/ml (5%) za infuziju;
The reconstituted product is isotonic.
Rekonstituirani lijek je izotoničan.
Adverse Drug Reaction Frequency Very Common
Učestalost nuspojava Vrlo često
Thus, each 2 ml of reconstituted solution provides 40 mg of parecoxib.
Tako svakih 2 ml pripremljene otopine osigurava 40 mg parekoksiba.
Patients received low-dose acetylsalicylic acid prior to randomization and throughout the two CABG surgery studies.
Prije randomizacije i tijekom cijelog trajanja ta dva kirurška ispitivanja primjene kod operacije ugradnje aortokoronarne premosnice bolesnici su primali nisku dozu acetilsalicilne kiseline.
Some people may be given lower doses: ▪ People with liver problems ▪ People with severe kidney problems ▪ Patients over 65 who weigh less than 50 kg ▪ People taking fluconazole.
• bolesnika u dobi iznad 65 godina s tjelesnom težinom manjom od 50 kg
Uncommon: may affect up to 1 in 100 people ▪ Heart attack ▪ There is a risk of cerebrovascular disease e.g. stroke, or transient ischaemic attack (transient reduced blood flow to the brain)/mini-stroke or angina, or blockages to blood vessels to the heart or brain ▪ Blood clot in the lungs ▪ Worsening of high blood pressure ▪ Ulcers in the digestive system, chronic stomach acid reflux ▪ The heart may beat more slowly
• postoji rizik od cerebrovaskularne bolesti, npr. moždanog udara ili prolaznog ishemijskog napadaja (prolazno smanjenje protoka krvi kroz mozak)/malog moždanog udara ili angine, ili začepljenja krvnih žila srca ili mozga
Blood creatinine increased
• pogoršanje povišenog krvnog tlaka
Immune system disorders
Poremećaji imunološkog sustava anafilaktoidna reakcija
▪ Acetylsalicylic acid (aspirin) or other anti-inflammatory medicines ▪ Fluconazole - used for fungal infections ▪ ACE inhibitors, Angiotensin-II inhibitors, beta blockers and diuretics - used for high blood pressure and heart conditions ▪ Ciclosporin or Tacrolimus - used after transplants ▪ Warfarin - or other warfarin like medicines used to prevent blood clots including newer medicines like apixaban, dabigatran, and rivaroxaban
• varfarin - ili drugi lijekovi nalik varfarinu koji se primjenjuju za sprječavanje nastanka krvnih ugrušaka uključujući novije lijekove kao što je apiksaban, dabigatran i rivaroksaban
Reactions might include wheezing (bronchospasm), badly blocked nose, itchy skin, rash or swelling of the face, lips or tongue, other allergic reactions or nasal polyps after taking these medicines - if you are more than 6 months pregnant - if you are breast-feeding - if you have severe liver disease - if you have inflammation of the intestines (ulcerative colitis or Crohn's disease) - if you have heart failure - if you are about to have heart surgery or surgery on your arteries (including any coronary artery procedure)
Reakcije mogu uključivati piskanje u plućima (bronhospazam), jako začepljen nos, svrbež kože, osip ili oticanje lica, usana ili jezika; druge alergijske reakcije ili nosne polipe nakon primjene tih lijekova
Dyspnoea
• mučnina
Musculoskeletal and connective tissue disorders Back pain Arthralgia Renal and urinary disorders Oliguria
Poremećaji bubrega i mokraćnog sustava oligurija akutno zatajenje bubrega zatajenje bubrega
Parecoxib is a prodrug of valdecoxib.
Parekoksib je predlijek valdekoksiba.
Dynastat 40 mg powder for solution for injection
Dynastat 40 mg prašak za otopinu za injekciju
▪ If you are dehydrated - this may happen if you have had diarrhoea or have been vomiting (being sick) or unable to drink fluids ▪ If you have an infection as it may hide a fever (which is a sign of infection) ▪ If you use medicines to reduce blood clotting (e.g. warfarin/warfarin like anticoagulants or novel oral anti-clotting medicines, e.g. apixaban, dabigatran, and rivaroxaban) ▪ If you use medicines called corticosteroids (e.g. prednisone) ▪ If you use a class of medicines used to treat depression called selective serotonin re-uptake inhibitors (e.g. sertraline)
• ako uzimate lijekove za smanjenje zgrušavanja krvi (npr. varfarin/antikoagulansi nalik varfarinu ili novi oralni lijekovi protiv zgrušavanja, npr. apiksaban, dabigatran i rivaroksaban)
Hepatic impairment
• zatajenje srca
If there are particles in the injection solution or if either the powder or solution is discoloured, the solution will not be used.
Ovaj lijek se ne smije upotrijebiti ako primijetite da su prisutne čestice u otopini za injekciju ili ako su prašak ili otopina promijenili boju.
• sodium chloride 4.5 mg/ml (0.45%) and glucose 50 mg/ml (5%) solution for injection/infusion; or
• otopina natrijevog klorida 4,5 mg/ml (0,45%) i glukoze 50 mg/ml (5%) za injekciju/infuziju; ili
Gastrointestinal disorders Nausea Abdominal pain, vomiting, constipation, dyspepsia, flatulence
Poremećaji probavnog sustava mučnina bolovi u abdomenu, povraćanje, konstipacija, dispepsija, flatulencija gastroduodenalni ulkus, gastroezofagealna refluksna bolest, suha usta, poremećeni gastrointestinalni zvukovi pankreatitis, ezofagitis, edem usta (perioralno oticanje)
Use aseptic technique to reconstitute lyophilised parecoxib (as parecoxib sodium).
Da biste rekonstituirali liofilizirani parekoksib (u obliku parekoksiba), primjenite aseptičku tehniku.
Dynastat 40 mg powder for solution for injection Parecoxib
Dynastat 40 mg prašak za otopinu za injekciju parekoksib
Appropriate measures should be taken and discontinuation of parecoxib therapy should be considered if there is clinical evidence of deterioration in the condition of specific clinical symptoms in these patients.
Ako postoji klinički dokaz pogoršanja stanja specifičnih kliničkih simptoma u tih bolesnika, moraju se poduzeti odgovarajuće mjere i razmotriti prekid terapije parekoksibom.
• sodium chloride 4.5 mg/ml (0.45%) and glucose 50 mg/ml (5%) solution for injection/infusion.
• otopina natrijevog klorida 4,5 mg/ml (0,45%) i glukoze 50 mg/ml (5%) za injekciju/infuziju.
Reporting of side effects
Ispitivanja učinaka na trombocite
Ear and labyrinth disorders
Poremećaj uha i labirinta bol u uhu
• sodium chloride 4.5 mg/ml (0.45%) and glucose 50 mg/ml (5%) solution for injection/infusion
• otopina natrijevog klorida 4,5 mg/ml (0,45%) i glukoze 50 mg/ml (5%) za injekciju/infuziju
• sodium chloride 4.5 mg/ml (0.45%) and glucose 50 mg/ml (5%) solution for injection/infusion;
• otopina natrijevog klorida 4,5 mg/ml (0,45%) i glukoze 50 mg/ml (5%) za injekciju/infuziju;
Dynastat 40 mg powder and solvent for solution for injection
Dynastat 40 mg prašak i otapalo za otopinu za injekciju
Dynastat 40 mg powder and solvent for solution for injection parecoxib
Dynastat 40 mg prašak i otapalo za otopinu za injekciju parekoksib
Thrombocytopenia
• omaglica
Fluid retention, oedema, renal
Zadržavanje tekućine, edem, bubrežni učinci
wheezing, difficulty breathing or swallowing (potentially fatal) ▪ Swelling, blistering or peeling of the skin ▪ Acute kidney failure ▪ Hepatitis (inflamed liver) ▪ Inflammation of the gullet (oesophagus) ▪ Inflammation of the pancreas (can lead to stomach pain)
Poremećaji metabolizma i prehrane hipokalemija hiperglikemija, anoreksija Psihijatrijski poremećaji: agitacija, nesanica Poremećaji živčanog sustava hipoestezija, omaglica cerebrovaskularni poremećaj
It must not be used in women who are more than three months pregnant.
Ne smiju ga uzimati žene koje su trudne dulje od tri mjeseca.
The maximum dose is one tablet of the highest strength (80/10 mg) once a day.
Maksimalna doza je jedna tableta najveće snage (80/10 mg) jednom na dan.
Both are medicines to lower the blood pressure that have been available in the European Union (EU) since the 1990s.
Oba se lijeka koriste za snižavanje krvnoga tlaka i dostupna su u Europskoj uniji (EU) od 1990.-ih.
Because telmisartan and amlodipine have been used for many years, the company presented information from scientific literature as well as results from new studies that the company had carried out.
Budući da su telmisartan i amlodipin u primijeni već dugi niz godina, tvrtka je dostavila informacije iz znanstvene literature kao i rezultate iz novih ispitivanja koje je tvrtka provela.
It is available as tablets (40 mg telmisartan/10 mg amlodipine, 40 mg telmisartan/5 mg amlodipine, 80 mg telmisartan/10 mg amlodipine and 80 mg telmisartan/5 mg amlodipine).
Lijek je dostupan kao tablete (40 mg telmisartana/10 mg amlodipina, 40 mg telmisartana/5 mg amlodipina, 80 mg telmisartana/10 mg amlodipina te 80 mg telmisartana/5 mg amlodipina).
The main measure of effectiveness in the three studies was the fall in diastolic blood pressure (blood pressure measured between two heartbeats) after eight weeks.
Glavna mjera učinkovitosti u tri ispitivanja bilo je smanjenje dijastoličkog krvnog tlaka (krvni tlak izmjeren između dva otkucaja srca) nakon osam tjedana.
It blocks special channels on the surface of cells called calcium channels, through which calcium ions normally enter the cells.
Blokira posebne kanale na površini stanica naziva kalcijevi kanali, kroz koje normalno ulaze ioni kalcija u stanice.
Twynsta telmisartan / amlodipine
Twynsta telmisartan / amlodipin
The European Commission granted a marketing authorisation valid throughout the EU for Twynsta on 7 October 2010.
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Twynsta na snazi u Europskoj uniji od 7. listopada 2010.
This is a summary of the European public assessment report (EPAR) for Twynsta.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Twynsta.
Twynsta is taken by mouth as one tablet once a day and is used for long-term treatment.
Twynsta se uzima peroralno kao jedna tableta na dan i koristi se za dugoročno liječenje.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Twynsta.
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Twynsta.
When appropriate, direct switch to Twynsta may be considered.
Ako je primjereno, može se razmotriti mogućnost izravnog prelaska na lijek Twynsta.
They work in similar ways to reduce blood pressure by allowing the blood vessels to relax.
Djeluju na slične načine kako bi smanjili krvni tlak, opuštanjem krvnih žila.
Telmisartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Telmisartan je „antagonist receptora angiotenzina II”, što znači da blokira rad hormona angiotenzina II u tijelu.
When calcium ions enter the cells in the muscles of blood vessel walls, this causes contraction.
Ulazak ioni kalcija u stanice u mišićima stjenki krvnih žila uzrokuje kontrakciju.
Twynsta must not be used in people who may be hypersensitive (allergic) to telmisartan, amlodipine, other medicines in the ‘dihydropyridine derivatives' class or to any of the other ingredients.
Twynsta se ne smije koristiti u osoba koje bi mogle biti preosjetljive (alergične) na telmisartan, amlodipin, ili druge lijekove u klasi "derivata dihidropiridina" ili na bilo koji drugi sastojak.
In the two other studies, Twynsta was more effective at reducing diastolic blood pressure than continued treatment with amlodipine alone: depending on the strengths of Twynsta and amlodipine, the fall in diastolic blood pressure was greater in patients taking Twynsta by between 1.4 mmHg and 4.9 mmHg.
U druga dva ispitivanja, Twynsta je bio djelotvorniji u smanjivanju dijastoličkog krvnog tlaka u odnosu na nastavljenu terapiju samo s amlodipinom; ovisno o jačini lijeka Twynsta i amlodipina, pad u dijastoličkom krvnom tlaku bio je veći u bolesnika koji su uzimali Twynsta između 1,4 mmHg i 4,9 mmHg.
Twynsta must not be used in patients who have severe liver or bile problems, shock (a steep fall in blood pressure), obstruction to blood flow from the left side of their heart or in patients with heart failure after having a myocardial infarction (heart attack).
Twynsta se ne smije koristiti u bolesnika koji imaju ozbiljne probleme s jetrom ili žući, dožive šok (nagli pad krvnog tlaka), opstrukciju protoka krvi s lijeve strane srca ili u bolesnika sa zatajenjem srca nakon infarkta miokarda (srčanog udara).
The most common side effects with Twynsta (seen in up to 1 patient in 10) are dizziness and peripheral oedema (swelling, especially of the ankles and feet).
Najčešće nuspojave lijeka Twynsta (zabilježene u više od 1 na 10 bolesnica) su vrtoglavica i periferni edem (oticanje, posebno gležnjeva i stopala).
In addition, studies showed that the medicine was effective in patients whose blood pressure is not adequately controlled by amlodipine alone.
Nadalje, ispitivanja su pokazala da je lijek učinkovitiji u bolesnika čiji se krvni tlak ne može primjereno kontrolirati samo amlodipinom.
Studies were also carried to show that Twynsta tablets are absorbed in the same way in the body as separate tablets of amlodipine and telmisartan.
Ispitivanja su također provedena kako bi se dokazalo da se tablete lijeka Twynsta apsorbiraju na isti način u tijelu kao zasebne tablete amlodipina i telmisartana.
In two other main studies, 1,978 adults whose hypertension had not responded adequately to amlodipine were either given Twynsta or continued to take amlodipine at the same or a higher dose.
U druga dva glavna ispitivanja, 1 978 odraslih osoba koje su imale hipertenziju, a nisu primjereno odgovorile na amlodipin primile su lijek Twynsta ili su nastavile uzimati amlodipin u istoj ili većoj dozi.
By blocking the receptors to which angiotensin II normally attaches, Telmisartan stops the hormone having an effect, allowing the blood vessels to widen.
Blokiranjem receptora na koja se angiotenzin II inače veže, telmisartan sprječava učinak hormona i omogućuje širenje krvnih žila.
What is Twynsta?
Što je Twynsta?
By reducing the flow of calcium into the cells, amlodipine prevents the cells from contracting and this helps the blood vessels to relax.
Smanjujući protok kalcija u stanicama, amlodipin sprječava kontrakciju stanica te na taj način omogućava opuštanje krvnih žila.
For a patient whose blood pressure is not adequately controlled by amlodipine, separate tablets of amlodipine and telmisartan should be used to adjust the doses before switching to Twynsta.
U slučaju bolesnika čiji krvni tlak nije primjereno kontroliran amlodipinom, treba koristiti zasebne tablete amlodipina i telmisartana s prilagođenim dozama prije prelaska na lijek Twynsta.
What is the risk associated with Twynsta?
Koji su rizici povezani s lijekom Twynsta?
The CHMP noted that patients already taking the two active substances in separate tablets may be more likely to adhere to their treatment if prescribed Twynsta.
CHMP je zaključio kako je izglednije da će se bolesnici koji već uzimaju dvije djelatne tvari kao zasebne tablete pridržavati terapije ako im se propiše samo Twynsta.
Other information about Twynsta:
Ostale informacije o lijeku Twynsta
Twynsta is used in patients whose blood pressure is not adequately controlled by amlodipine alone.
Twynsta se primjenjuje u bolesnika čiji se krvni tlak ne može primjereno kontrolirati samo terapijom amlodipinom.
The Committee decided that Twynsta's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je odlučio da koristi lijeka Twynsta nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
In one main study, 1,461 adults with hypertension were treated with combinations of telmisartan and amlodipine, with telmisartan or amlodipine alone, or with placebo (a dummy treatment).
U jednom glavnom ispitivanju, 1. 61 odraslih osoba s hipertenzijom liječeno je kombinacijama telmisartana i amlodipina, monoterapijom telmisartana ili amlodipina ili placebom (liječenjem bez djelatne tvari).
Twynsta can also be used in place of treatment with telmisartan and amlodipine in patients who are taking both medicines as separate tablets.
Twynsta se može također koristiti umjesto terapije telmisartanom i amlodipinom u bolesnika koji uzimaju ova lijeka kao zasebne tablete.
In the first study, the falls in diastolic blood pressure seen in patients taking combinations of telmisartan and amlodipine were greater than those seen in patients taking only one of the active substances or placebo.
U prvom ispitivanju, pad u dijastoličkom krvnom tlaku u bolesnika koji su uzimali kombinaciju telmisartana i amlodipina bio je veći od onoga koji je uočen u bolesnika koji su uzimali samo jednu djelatnu tvar ili placebo.
Twynsta is a medicine that contains two active substances, telmisartan and amlodipine.
Twynsta je lijek koji sadrži dvije djelatne tvari, telmisartan i amlodipin.
For a patient who has been taking telmisartan and amlodipine as separate tablets, the dose of Twynsta to be taken depends on the doses of telmisartan and amlodipine that he or she was taking before.
U slučaju bolesnika koji su uzimali telmisartan i amlodipin kao zasebne tablete, doza lijeka Twynsta koja će se uzimati ovisi o dozama telmisartana i amlodipina koje je bolesnik uzimao ranije.
Twynsta must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.
Twynsta se ne smije uzimati u kombinaciji s lijekovima koji sadrže aliskiren (također se koristi za liječenje esencijalne hipertenzije) kod bolesnika s dijabetesom tipa 2 ili umjerenim do teškim oštećenjem bubrega.
Why has Twynsta been approved?
Zašto je lijek Twynsta odobren?
Twynsta contains two active substances, telmisartan and amlodipine.
Twynsta sadrži dvije djelatne tvari, telmisartan i amlodipin.
The full EPAR for Twynsta can be found on the Agency's website under EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Cjeloviti EPAR za lijek Twynsta nalazi se na internetskim stranicama Agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports Više informacija o terapiji lijekom Twynsta pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svojem liječniku ili ljekarniku.
For the full list of all side effects reported with Twynsta, see the package leaflet.
Potpuni popis svih nuspojava zabilježenih pri primjeni lijeka Twynsta potražite u uputi o lijeku.
Twynsta is used to treat essential hypertension (high blood pressure) in adults (aged 18 years or over).
Twynsta se koristi za liječenje esencijalne hipertenzije (visokog krvnog tlaka) u odraslih osoba (u dobi od 18 godina ili starijih). „Esencijalno” znači da ne postoji očiti uzrok hipertenzije.
What is Twynsta used for?
Za što se Twynsta koristi?
What benefit has Twynsta shown during the studies?
Koje su koristi lijeka Twynsta utvrđene u ispitivanjima?
How is Twynsta used?
Kako se Twynsta koristi?
How has Twynsta been studied?
Kako je Twynsta ispitivan?
How does Twynsta work?
Kako djeluje Twynsta?
ATCvet code: QI06AH09.
ATCvet kod: QI06AH09.
Date of first authorisation: 23/02/2005 Date of last renewal: 25/01/2010
Datum prvog odobrenja: 23/02/2005 Datum posljednje obnove: 25/01/2010
Shelf life of the veterinary medicinal product as packaged for sale: 18 months.
Rok valjanosti veterinarsko-medicinskog proizvoda kad je zapakiran za prodaju:18 mjeseci.
EXP (mm/yyyy)
EXP {mm/gggg}
EU/2/04/052/001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/052/002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
EU/2/04/052/001 Liofilizat (10 bočica s po 1 dozom) + otapalo (10 bočica od 1 ml) EU/2/04/052/002 Liofilizat (50 bočica s po 1 dozom) + otapalo (50 bočica od 1 ml)
FHV (F2 strain) ................................................................................................................. ≥ 104.9 CCID50 FCV (431 and G1 strains) ............................................................................................... ≥ 2.0 ELISA U. FPV (PLI IV) .................................................................................................................... ≥ 103.5 CCID50.
FHV (soj F2) ..................................................................................................................... ≥ 104,9 CCID50 FCV (soj 431 i G1) .......................................................................................................... ≥ 2,0 ELISA U. FPV (PLI IV) ..................................................................................................................... ≥ 103,5 CCID50.
In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days).
U normalnim uvjetima primjene, povremeno se mogu javiti apatija i anoreksija, kao i hipertermija (obično u trajanju 1 ili 2 dana).
Active immunisation of cats aged 8 weeks and older: - against feline viral rhinotracheitis to reduce clinical signs, - against calicivirus infection to reduce clinical signs, - against feline panleucopenia to prevent mortality and clinical signs.
Aktivna imunizacija mačaka starijih od 8 tjedana: - protiv virusnog rinotraheitisa mačaka za smanjenje kliničkih znakova, - protiv infekcije kalici virusom za smanjenje kliničkih znakova, - protiv panleukopenije mačaka za sprječavanje smrtnosti i kliničkih znakova.
4.2 Indications for use
4.2 Indikacije za primjenu
4.5 Special precautions for use Special precautions for use in animals
4.5 Posebne mjere predostrožnosti za primjenu Posebne mjere predostrožnosti za primjenu na životinjama
Water for injection ....................................................................................................................... q.s.
Voda za injekcije .......................................................................................................................... q.s. 1 ml